·
October 19, 2018 – In a feature interview with GenomeWeb, SeekIn founder Mao Mao discusses the company’s machine learning-driven approach to multi-cancer early detection and its plans to raise Series A funding for clinical validation. Mao shares insights on the real-world utility of detecting aggressive cancers, the design of upcoming prospective studies, and SeekIn’s vision for an accessible, low-cost screening test aimed at reducing cancer mortality.